Coated, Impregnated, Or Colloidal Particulate (e.g., Microcapsule, Micro-sphere, Micro-aggregate, Macro-aggregate) Patents (Class 424/1.29)
  • Patent number: 10207014
    Abstract: An imaging nanoparticle comprising a plant virus particle having an interior surface and an exterior surface, an imaging agent that is linked to the interior and/or exterior surface, and a layer of biocompatible mineral such as silica coated over the exterior surface, is described. The imaging nanoparticle can be used in method of generating an image of a tissue region of a subject, by administering to the subject a diagnostically effective amount of an imaging nanoparticle and generating an image of the tissue region of the subject to which the imaging nanoparticle has been distributed.
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: February 19, 2019
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Nicole F. Steinmetz, Michael Bruckman, Lauren Randolph
  • Patent number: 10182979
    Abstract: The present disclosure describes a plurality of microspheres that include carboxymethyl chitosan (CCN) crosslinked with carboxymethyl cellulose (CMC). The microspheres are biocompatible, bioresorbable, and biodegradable. The microspheres may be used in personal care products, such as, for example, toothpaste, topical pain relief products, topical antibiotic products, skincare products such as anti-wrinkle products, eczema products, skin scrubs, acne cleansers, exfoliators, body washes, soaps, pre-shave creams, or the like.
    Type: Grant
    Filed: March 22, 2017
    Date of Patent: January 22, 2019
    Assignees: Regents of the University of Minnesota, EmboMedics, Inc.
    Inventors: Lihui Weng, Jafar Golzarian, Omid Souresrafil
  • Patent number: 9925281
    Abstract: An imaging nanoparticle comprising a plant virus particle having an interior surface and an exterior surface, an imaging agent that is linked to the interior and/or exterior surface, and a layer of biocompatible mineral such as silica coated over the exterior surface, is described. The imaging nanoparticle can be used in method of generating an image of a tissue region of a subject, by administering to the subject a diagnostically effective amount of an imaging nanoparticle and generating an image of the tissue region of the subject to which the imaging nanoparticle has been distributed.
    Type: Grant
    Filed: August 5, 2015
    Date of Patent: March 27, 2018
    Assignee: Case Western Reserve University
    Inventors: Nicole F. Steinmetz, Michael Bruckman, Lauren Randolph
  • Patent number: 9844680
    Abstract: The invention relates to a computer-aided simulation tool, in particular to computer-aided simulation methods, for providing assistance in the planning of thermotherapy, and to suitably configured computer equipment. The thermotherapy comprises hyperthermic treatment of a tumour volume within a volume of a human body. The hyperthermic treatment comprises the application of a magnetic field within a treatment volume by means of a magnetic field applicator. In at least one depot volume, thermal energy can be introduced by means of magnetic, paramagnetic and/or superparamagnetic nanoparticles deposited in the body, by power absorption in the applied magnetic field. Field strength values and optionally calculated temperature distributions are provided for assisting the user in the planning of the thermotherapy.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: December 19, 2017
    Assignee: MAGFORCE AG
    Inventors: Jacek Nadobny, Peng Liu, Jens-Thorsten Ollek, Heike C. Bender
  • Patent number: 9820991
    Abstract: The present invention provides an improved novel process of manufacturing a sterile, ophthalmic pharmaceutical suspension comprising an active ingredient(s) such as carbonic anhydrase inhibitors (CAIs) wherein the said process involves solubilization, followed by controlled precipitation of carbonic anhydrase inhibitors of the right particle size, e.g., less than 10 micron, preferably less than 5 micron (D90) by varying pH with a little or no homogenization. Said process further does not require the use of any special equipment such as ball mill, milling bottle and/or jet mill. This newly improved process is simple, cost effective and efficient.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: November 21, 2017
    Assignee: SENTISS PHARMA PRIVATE LIMITED
    Inventors: Mandar Shah, Divya Pandit, Deepak Bahri
  • Patent number: 9272918
    Abstract: The synthetic amorphous silica powder of the present invention is characterized in that it comprises a synthetic amorphous silica powder obtained by applying a spheroidizing treatment to a silica powder, and by subsequently cleaning and drying it so that the synthetic amorphous silica powder has an average particle diameter D50 of 10 to 2,000 ?m; wherein the synthetic amorphous silica powder has: a quotient of 1.00 to 1.35 obtained by dividing a BET specific surface area of the powder by a theoretical specific surface area calculated from the average particle diameter D50; a real density of 2.10 to 2.20 g/cm3; an intra-particulate porosity of 0 to 0.05; a circularity of 0.75 to 1.00; and a spheroidization ratio of 0.55 to 1.00.
    Type: Grant
    Filed: December 24, 2010
    Date of Patent: March 1, 2016
    Assignee: MITSUBISHI MATERIALS CORPORATION
    Inventor: Toshiaki Ueda
  • Patent number: 9211283
    Abstract: Compositions, which are stable in storage, and a method of production of pharmaceutical based nanoparticulate formulations for photodynamic therapy comprising a hydrophobic photosensitizer, human serum albumin (HSA) and stabilizing agent are provided. These nanoparticulate formulations provide therapeutically effective amounts of photosensitizer (PS) for parenteral administration. In particular, tetrapyrrole derivatives can be used as photosensitizers whose efficacy and safety are enhanced by such nanoparticulate formulations. A method of preparing the HSA-based nanoparticles under sterile conditions is also provided. In one of the preferred embodiments of the present invention temoporfin, a hydrophobic PS, is formulated as a nanoparticle for parenteral administration. The formulations are useful for treating hyperplasic and neoplasic conditions, inflammatory problems, and more specifically to target tumor cells.
    Type: Grant
    Filed: November 8, 2010
    Date of Patent: December 15, 2015
    Assignee: Biolitec Pharma Marketing Ltd
    Inventors: Klaus Langer, Matthias Wacker, Beate Röder, Annegret Preuss, Volker Albrecht, Susanna Gräfe, Arno Wiehe, Hagen von Briesen, Karin Löw, Sylvia Wagner
  • Patent number: 9120678
    Abstract: The synthetic amorphous silica powder of the present invention is characterized in that it comprises a synthetic amorphous silica powder obtained by applying a spheroidizing treatment to a silica powder, and by subsequently cleaning and drying it so that the synthetic amorphous silica powder has an average particle diameter D50 of 10 to 2,000 ?m; wherein the synthetic amorphous silica powder has: a quotient of 1.00 to 1.35 obtained by dividing a BET specific surface area of the powder by a theoretical specific surface area calculated from the average particle diameter D50; a real density of 2.10 to 2.20 g/cm3; an intra-particulate porosity of 0 to 0.05; a circularity of 0.75 to 1.00; and an unmolten ratio of 0.00 to 0.25.
    Type: Grant
    Filed: December 24, 2010
    Date of Patent: September 1, 2015
    Assignee: MITSUBISHI MATERIALS CORPORATION
    Inventor: Toshiaki Ueda
  • Patent number: 9107831
    Abstract: Immunogenic compositions comprising microparticles with adsorbed toxoid antigen and/or polysaccharide-containing antigen are disclosed. The immunogenic microparticle compositions comprise (a) polymer microparticles comprising a biodegradable polymer; (b) an antigen adsorbed to the microparticles selected from (i) a toxoid antigen, such as a tetanus toxoid, a diphtheria toxoid, or a combination thereof, and/or (ii) a polysaccharide containing antigen, such as a Hib polysaccharide antigen, a Hib conjugate antigen comprising polysaccharide and polypeptide regions, a meningococcal polysaccharide antigen, a meningococcal conjugate antigen comprising polysaccharide and polypeptide regions, a pneumococcal polysaccharide antigen, and a pneumococcal conjugate antigen comprising polysaccharide and polypeptide regions or a combination thereof; and (c) a pharmaceutically acceptable excipient.
    Type: Grant
    Filed: June 2, 2004
    Date of Patent: August 18, 2015
    Assignee: Novartis Vaccines and Diagonstics, Inc.
    Inventor: Derek O'Hagan
  • Patent number: 9028797
    Abstract: The invention provides an antigen or drug delivery complex containing a complex of an antigen or drug and a cationic molecule, and an anionic molecule encapsulating the same. The antigen or drug delivery complex can be used as a main component of a drug delivery system that delivers various antigens and drugs to a particular cell or organ.
    Type: Grant
    Filed: February 24, 2011
    Date of Patent: May 12, 2015
    Assignees: Nagasaki University, Kyusyu University Corporation, National University Corporation Hamamatsu University School of Medicine
    Inventors: Hitoshi Sasaki, Tomoaki Kurosaki, Takashi Kitahara, Hideto To, Katsuyuki Yui, Kenji Hirayama, Kouichi Morita, Takahiro Mukai, Yasuhiro Magata, Mikako Ogawa, Kohei Sano
  • Patent number: 9023314
    Abstract: A surface coating for a medical device is provided that may prevent or slow the formation of medical biofilms on the surface of the device. Covalent attachment of certain analogues of N-acyl L-homoserine lactones onto a medical device may provide the advantage of slowing biofilm formation in a manner that is targeted to the surface of the medical device and not the patient. Such a device may allow healthcare providers to prevent bacterial buildups on the surfaces of the device, which may lead to biofilm formation.
    Type: Grant
    Filed: September 30, 2009
    Date of Patent: May 5, 2015
    Assignee: Covidien LP
    Inventor: Michael P. O'Neil
  • Patent number: 9017643
    Abstract: A process for making particles comprising a hydrophobic dopant for subsequent release therefrom is disclosed. The process comprises providing an emulsion comprising a hydrophilic phase and a hydrophobic phase dispersed in the hydrophilic phase, and reacting the precursor material to form the particles comprising the dopant therein. The hydrophobic phase comprises a precursor material and the dopant.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: April 28, 2015
    Assignee: Australian Nuclear Science & Technology Organisation
    Inventors: Kim Suzanne Finnie, Christophe Jean Alexandre Barbe, Linggen Kong
  • Publication number: 20150110713
    Abstract: A method for treating cancer, preventing cancer or delaying the progression of a cancer in an animal or human comprising the step of: administering to the animal or the human having a cancer a composition in an amount effective to treat cancer, prevent cancer or delay the progression of cancer in the animal or the human. The composition comprises a pharmaceutically acceptable excipient, and ascorbate which is joined to a carrier structure containing an anti-cancer active agent, said carrier structure being capable of releasing the anti-cancer agent in the presence of a reactive oxygen species.
    Type: Application
    Filed: December 22, 2014
    Publication date: April 23, 2015
    Inventors: Anthony Manganaro, Karen Rockwell
  • Publication number: 20150098899
    Abstract: Timed-bioresorbable particulates, particularly microspheres or fibers, may be used as a vehicle for delivery of radioisotopes, such as Y-90 and Pd-103 for localized radiotherapy, or as an embolic device. These particulates may also be embedded in polymers, or dispersed in injectable gels or other injectable media for the treatment of various cancers. The benefit of bioresorption, the ability to control the ratio of radioisotopes in the particulate, especially the gamma and beta ratios such as In-111/Y-90 ratio in a particulate, and the benefit of non-conductive implants are disclosed.
    Type: Application
    Filed: March 24, 2014
    Publication date: April 9, 2015
    Applicant: XL Sci-Tech, Inc.
    Inventors: Yongren Benjamin PENG, Xingye Cherry Lei
  • Publication number: 20150064107
    Abstract: The invention relates to imaging agents, and in particular to multi-modal nanoparticle (NPIA) imaging agents offering magnetic, radionuclide and fluorescent imaging capabilities to exploit the complementary advantages of magnetic resonance imaging (MRI), positron emission tomography (PET), single-photon emission computed tomography (SPECT) and optical imaging (OI). The invention extends to these new types of agents per se, and to uses of such agents in various biomedical applications, such as in therapy and in diagnosis.
    Type: Application
    Filed: August 28, 2014
    Publication date: March 5, 2015
    Applicant: King's College London
    Inventors: Xianjin Cui, Philip Blower, Mark A. Green
  • Patent number: 8968699
    Abstract: The invention provides nanodevices or products of manufacture for use as drug delivery vehicles. In one aspect, the invention provides nanodevices or products of manufacture having on-off release mechanisms, e.g., that are “switchable”, or “actuatable” (for example magnetically or ultrasonically switchable), for compounds contained within, e.g., for use as drug delivery nano-vehicles having on-off drug release mechanisms, and their therapeutic applications.
    Type: Grant
    Filed: November 14, 2008
    Date of Patent: March 3, 2015
    Assignee: The Regents of the University of California
    Inventors: Sungho Jin, Seunghan Oh, Karla Brammer, Seong Kong
  • Patent number: 8962030
    Abstract: Milled nanoparticles comprising a biologically active agent, at least one biopolymer and a coating containing at least one coating which is a polymer or ligand are produced using milling and coating techniques which have not previously been used for these applications.
    Type: Grant
    Filed: November 10, 2010
    Date of Patent: February 24, 2015
    Assignee: Jyant Technologies, Inc.
    Inventors: James W. Lillard, Rajesh Singh, Shailesh Singh
  • Patent number: 8961949
    Abstract: The present invention provides a polymer-metal complex composite, which comprises a block copolymer capable of serving as a constituent member of a polymeric micelle and a metal complex having MRI contrast ability, accumulates in a tumor-specific manner, achieves high image contrast even in a small amount, and has reduced side effects and a long retention time in blood. The polymer-metal complex composite of the present invention comprises a block copolymer (A) represented by general formula (a) and a metal complex (B) having MRI contrast ability, wherein the composite comprises a structure in which a carboxyl anion of poly(carbo) in the copolymer (A) is attached to the metal complex (B) via a metal atom (M).
    Type: Grant
    Filed: June 26, 2009
    Date of Patent: February 24, 2015
    Assignee: Japan Science and Technology Agency
    Inventors: Kazunori Kataoka, Sachiko Kaida, Horacio Cabral, Michiaki Kumagai, Masaki Sekino
  • Publication number: 20150037250
    Abstract: According to one embodiment, a contrast agent includes a blood vessel contrast enhancement particles configured to enhance contrast of a blood vessel of an object and a diseased tissue contrast enhancement particles configured to enhance contrast of a diseased tissue of the object. The blood vessel contrast enhancement particles have a first particle size larger than a gap of vascular endothelial cells under an EPR effect. The diseased tissue contrast enhancement particles have a second particle size smaller than the gap.
    Type: Application
    Filed: July 31, 2014
    Publication date: February 5, 2015
    Applicants: Kabushiki Kaisha Toshiba, Toshiba Medical Systems Corporation
    Inventor: Hitoshi YAMAGATA
  • Publication number: 20150004095
    Abstract: A process for making particles comprising a hydrophobic dopant for subsequent release therefrom is disclosed. The process comprises providing an emulsion comprising a hydrophilic phase and a hydrophobic phase dispersed in the hydrophilic phase, and reacting the precursor material to form the particles comprising the dopant therein. The hydrophobic phase comprises a precursor material and the dopant.
    Type: Application
    Filed: July 9, 2014
    Publication date: January 1, 2015
    Inventors: Kim Suzanne FINNIE, Christophe Jean Alexandre BARBE, Linggen KONG
  • Patent number: 8920775
    Abstract: The present invention relates to a novel composition and method for loading delivery systems such as liposome compositions with radionuclides useful in targeted diagnostic and/or therapy of target site, such as cancerous tissue and, in general, pathological conditions associated with leaky blood vessels. The composition and methods of the invention find particular use in diagnosing and imaging cancerous tissue and, in general, pathological conditions associated with leaky blood vessels in a subject. The present invention provides a new diagnostic tool for the utilization of positron emission tomography (PET) imaging technique. One specific aspect of the invention is directed to a method of producing nanoparticles with desired targeting properties for diagnostic and/or radio-therapeutic applications.
    Type: Grant
    Filed: July 16, 2010
    Date of Patent: December 30, 2014
    Assignees: Technical University of Denmark, Rigshospitalet
    Inventors: Anncatrine Luisa Petersen, Palle Hedengran Rasmussen, Jonas Rosager Henriksen, Andreas Kjær, Thomas Lars Andresen
  • Publication number: 20140377170
    Abstract: The invention relates to methods for producing papilloma-derived nanosphere particles that contain therapeutic, diagnostic, or other agents. The invention also provides nanosphere particle preparations that are useful for selectively delivering therapeutic, diagnostic, and/or other agents to cancer cells of subjects without eliciting a serotype-specific immunogenic response in the subjects.
    Type: Application
    Filed: February 7, 2013
    Publication date: December 25, 2014
    Applicant: Aura Biosciences, Inc.
    Inventors: Elisabet de los Pinos, Rhonda C. Kines
  • Patent number: 8906345
    Abstract: The invention provides multimeric particle comprising metal-containing particles covalently bonded to one another by linker groups wherein at least some of said linker groups are cleavable. The invention further provides a contrast agent comprising said multimeric particles, along with a method of improving contrast of an image using said contrast agent.
    Type: Grant
    Filed: September 20, 2007
    Date of Patent: December 9, 2014
    Assignee: Isis Innovation Limited
    Inventors: Daniel Anthony, Benjamin Guy Davis, Nicola Sibson
  • Publication number: 20140335015
    Abstract: The present invention relates to novel nanoparticles which can be advantageously used in the health sector as diagnostic and/or therapeutic agents. Nanoparticles of the invention comprise a metallic material at least partly covered with an hafnium oxide material or embedded therein. When compared to existing products, these nanoparticles offer a remarkable benefit over risk ratio. Specifically, these nanoparticles potentiate the efficiency of known metallic nanoparticles. Indeed, they retain the metal intrinsic properties and are now in addition safely usable in a mammal, in particular in a human being. The invention also relates to methods for producing said nanoparticles, to compositions containing same, and to uses thereof.
    Type: Application
    Filed: December 17, 2012
    Publication date: November 13, 2014
    Inventors: Agnes Pottier, Laurent Levy, Marie-Edith Meyre
  • Patent number: 8877156
    Abstract: The present invention is directed toward a multivalent product including a nanoparticle with a metal, metal alloy, or metal oxide core, a plurality of non-polymerizing ligands bound to the nanoparticle, and a plurality of paramagnetic ions coupled to the nanoparticle by the ligands. Methods of making and using the multivalent product are also disclosed.
    Type: Grant
    Filed: June 26, 2008
    Date of Patent: November 4, 2014
    Assignee: New York University
    Inventors: Marc A. Walters, Youssef Zaim Wadghiri
  • Publication number: 20140257100
    Abstract: The present invention relates to a microbubble comprising a monolayer of porphyrin-phospholipid conjugate, said microbubble having encapsulated therein, and to the use of said microbubble in ultrasound imaging of a target area in a subject.
    Type: Application
    Filed: October 11, 2012
    Publication date: September 11, 2014
    Applicant: UNIVERSITY HEALTH NETWORK
    Inventors: Gang Zheng, Jonathan Lovell, Elizabeth Huynh
  • Publication number: 20140248210
    Abstract: The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo.
    Type: Application
    Filed: March 17, 2014
    Publication date: September 4, 2014
    Applicants: CORNELL UNIVERSITY, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: Michelle Bradbury, Ulrich Wiesner, Oula Penate Medina, Andrew Burns, Jason Lewis, Steven Larson, Tom Quinn
  • Patent number: 8821835
    Abstract: A flexible or elastic brachytherapy strand that includes an imaging marker and/or a therapeutic, diagnostic or prophylactic agent such as a drug in a biocompatible carrier that can be delivered to a subject upon implantation into the subject through the bore of a brachytherapy implantation needle has been developed. Strands can be formed as chains or continuous arrays of seeds up to 50 centimeters or more, with or without spacer material, flaccid, rigid, or flexible.
    Type: Grant
    Filed: June 13, 2013
    Date of Patent: September 2, 2014
    Assignee: Microspherix LLC
    Inventor: Edward J. Kaplan
  • Publication number: 20140227176
    Abstract: A process for manufacturing magnetic and/or radioactive metal nanoparticles, the process comprising: preparing an electrolyte solution including metal ions and a stabilizer; generating a plasma at an interface of the electrolyte solution at atmospheric pressure; and recovering magnetic and/or radioactive metal nanoparticles. The magnetic metal nanoparticles can comprise magnetoradioactive nanoparticles. The magnetic metal nanoparticles can be used as MRI contrast agents and the magnetoradioactive nanoparticles can also be used as contrast agents and for dual PET/MRI applications. It also relates to a multi-plasma apparatus for synthesizing nanoparticles.
    Type: Application
    Filed: December 20, 2011
    Publication date: August 14, 2014
    Inventors: Fortin Marc-Andre, Christian Sarra-Bournet, Mathieu Letourneau, Gaetan Laroche
  • Patent number: 8795726
    Abstract: The present invention provides compositions for extended release of a nucleic acid agent, a biodegradable polymer. The present invention also provides methods of producing the matrix compositions and methods for using the matrix compositions to provide controlled release of the nucleic acid agent.
    Type: Grant
    Filed: January 18, 2011
    Date of Patent: August 5, 2014
    Assignee: Polypid Ltd.
    Inventors: Noam Emanuel, Yosef Rosenfeld
  • Publication number: 20140212355
    Abstract: It is provided herein methods, devices, and compositions for trans-arterial local delivery of therapeutic agent for the treatment of liver cancers.
    Type: Application
    Filed: January 28, 2013
    Publication date: July 31, 2014
    Applicant: Abbott Cardiovascular Systems Inc.
    Inventors: Mikael TROLLSAS, Syed Hossainy, John Stankus, Paul Consigny
  • Patent number: 8790706
    Abstract: The dentifrice powder comprises grains of ground pumice stone coated with particles of a dry extract of fruit tree leaves, in particular pawpaw leaves, and is preferably obtained by carrying out a method comprising the following steps: producing a decoction of fruit tree leaves in water; filtering the decoction using a sieve with a mesh of 100 ?m; adding ground pumice stone having grains with a maximum dimension of 100 ?m; and atomizing the mixture in a stream of hot air with an inlet temperature of close to 300° C. and an outlet temperature of close to 100° C.
    Type: Grant
    Filed: March 25, 2009
    Date of Patent: July 29, 2014
    Assignee: Gencix
    Inventor: Christophe Binachon
  • Publication number: 20140193331
    Abstract: Disclosed is a method of non-invasive infrared imaging, comprising (a) administering a composition containing infrared-emitting particles which contain rare earth elements that emit in the short-wavelength infrared (SWIR) spectrum, where the particles are encapsulated with a biocompatible matrix to form downconverting encapsulated particles; and (b) irradiating with infrared radiation, where both excitation and emission spectra of the encapsulated particles are in the infrared region. Analogous methods of image-guided biomedical intervention, and drug tracking and delivery are also disclosed. Also disclosed is a composition for biomedical applications, containing infrared-emitting particles which contain rare earth-elements that emit in the short-wavelength infrared (SWIR) spectrum, where the particles are encapsulated with a biocompatible matrix to form downconverting encapsulated particles.
    Type: Application
    Filed: May 7, 2012
    Publication date: July 10, 2014
    Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Dominik J. Naczynski, Mei-Chee Tan, Richard E. Riman, Charles Roth, Prabhas V. Moghe
  • Publication number: 20140178297
    Abstract: A contrast marker having a casing and a novel MRI contrast agent comprising metal complexes disposed around, within, or abuting the casing is provided. Such contrast markers may be placed in a strand, with or without a therapy seed, to produce a seeded strand useful for imaging and in connection with brachytherapy.
    Type: Application
    Filed: February 27, 2014
    Publication date: June 26, 2014
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Steven J. Frank, Karen Martirosyan
  • Patent number: 8709379
    Abstract: Formulations of neutral retinoids, in particular fenretinide (HPR) in the form of lipid nanoparticles, solid dispersions and emulsions are disclosed. These compositions are used to treat diseases that are amenable to treatment by HPR, such as neoplastic diseases by achieving higher and more prolonged concentrations of HPR in the subject. The key steps for preparing lipid nanovesicles of HPR include mixing and sonication, sterile filtration, without or without lyophilization for long-term stable storage, and employ processes and materials that are scalable from the laboratory to the manufacturing level. The formulation are suitable for injection into human or animal patients without causing allergic or hypersensitivity responses by avoiding chemical surfactants and animal sources of phospholipids in their manufacture.
    Type: Grant
    Filed: March 29, 2007
    Date of Patent: April 29, 2014
    Assignee: Scitech Development, LLC
    Inventors: Ralph E. Parchment, Bhaskara R. Jasti, Ramesh R. Boinpally, Stephen E. Rose, Earle T. Holsapple
  • Patent number: 8697129
    Abstract: In the present invention, a method of producing stable bare colloidal gold nanoparticles is disclosed. The nanoparticles can subsequently be subjected to partial or full surface modification. The method comprises preparation of colloidal gold nanoparticles in a liquid by employing a top-down nanofabrication method using bulk gold as a source material. The surface modification of these nanoparticles is carried out by adding one or multiple types of ligands each containing functional groups which exhibit affinity for gold nanoparticle surfaces to produce the conjugates. Because of the high efficiency and excellent stability of the nanoparticles produced by this method, the fabricated gold nanoparticle conjugates can have surface coverage with functional ligands which can be tuned to be any percent value between 0 and 100%.
    Type: Grant
    Filed: March 2, 2011
    Date of Patent: April 15, 2014
    Assignee: IMRA America, Inc.
    Inventors: Wei Qian, Makoto Murakami, Yuki Ichikawa, Yong Che
  • Publication number: 20140099256
    Abstract: An embodiment of the invention is directed to a composition comprising a luminescent noble metal nanoparticle, wherein the surface of the noble metal nanoparticle is coated with a ligand, and wherein the noble metal nanoparticle is about 2 nm to 5 nm in diameter and further wherein a portion of the noble metal is present as its radioactive isotope. In an embodiment of the invention, the radioactive isotope is present at a concentration of up to 2% w/w of the noble metal.
    Type: Application
    Filed: August 28, 2013
    Publication date: April 10, 2014
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Jie Zheng, Xiankai Sun
  • Publication number: 20140099255
    Abstract: The invention relates to a particulate material having a diameter in the range of from 5 to 200 microns comprising polymeric matrix and stably incorporated radionuclide, processes for its production and a method of radiation therapy utilising the particulate material.
    Type: Application
    Filed: August 16, 2013
    Publication date: April 10, 2014
    Applicant: Sirtex Medical Limited
    Inventor: Bruce Nathaniel Gray
  • Patent number: 8691280
    Abstract: The invention provides a microsphere comprising an organic lanthanide metal complex wherein the lanthanide metal is present in an amount of more than 20 wt %, based on total microsphere. The invention further provides a suspension comprising such a microsphere. In addition, the invention relates to a method for preparing said microsphere, and the use of the microsphere(s) or suspension for treating a malignancy and/or obtaining a scanning image.
    Type: Grant
    Filed: July 18, 2008
    Date of Patent: April 8, 2014
    Assignees: UMC Utrecht Holding B.V., Stichting voor de Technische Wetenschappen
    Inventors: Johannes F. W. Nijsen, Wouter Bult, Alfred D. van het Schip
  • Patent number: 8685962
    Abstract: Articles of manufacturing (such as tobacco products), methods, devices and compositions for preventing or reducing tobacco-associated damage and/or disorders associated with oxidative stress in a subject, and which utilize a TSPO receptor ligand (such as diazepam), are disclosed.
    Type: Grant
    Filed: July 2, 2008
    Date of Patent: April 1, 2014
    Assignee: Technion Research & Development Foundation Limited
    Inventors: Moshe Gavish, Rafael M. Nagler
  • Patent number: 8685367
    Abstract: Preferred embodiments relate to compositions of inherently radiopaque, biocompatible, bioresorbable polymeric particles and methods of using them for embolizing a body lumen.
    Type: Grant
    Filed: September 27, 2004
    Date of Patent: April 1, 2014
    Assignee: Rutgers, The State University of of New Jersey
    Inventors: Donald K. Brandom, Eric Schmid, Joan Zeltinger, Durgadas Bolikal, Joachim B. Kohn
  • Patent number: 8679454
    Abstract: Surface coatings including microparticles immobilized in a matrix of polymeric material on a substrate are described. The microparticles can also include an agent which can be useful for various applications, such as medical applications. This invention relates to the field of surface coatings for use in various applications. More particularly, the invention relates to surface coating useful for drug delivery, imaging and other uses of microparticles immobilized via a polymeric matrix.
    Type: Grant
    Filed: March 27, 2009
    Date of Patent: March 25, 2014
    Assignee: Surmodics, Inc.
    Inventors: Patrick E. Guire, Kristin S. Taton, John V. Wall
  • Patent number: 8673266
    Abstract: The present invention relates to microspheres useful for embolization which comprises polyvinylalcohol. The present invention also relates to an injectable suspension suitable for embolization which comprises the polyvinylalcohol microspheres and a suitable liquid carrier. The present invention further relates to a method for prophylactic or therapeutic embolization which comprises administering to a mammal an injectable suspension containing the polyvinylalcohol microspheres and a suitable liquid carrier. Finally, the present invention relates to a process for producing the polyvinylalcohol microspheres.
    Type: Grant
    Filed: January 12, 2010
    Date of Patent: March 18, 2014
    Assignee: Biosphere Medical, S.A.
    Inventor: Egisto Boschetti
  • Patent number: 8617516
    Abstract: The present invention provides a substantially non-lytic, non-cytotoxic anchor peptide that is capable of stably inserting into lipid membranes. In particular, the invention provides nanoparticles comprising stably inserted anchor peptides, which may be conjugated to a variety of different cargo complexes.
    Type: Grant
    Filed: October 22, 2010
    Date of Patent: December 31, 2013
    Assignee: Washington University
    Inventors: Samuel A. Wickline, Hua Pan, Neelesh R. Soman, Gregory M. Lanza, Paul H. Schlesinger
  • Patent number: 8613937
    Abstract: Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue.
    Type: Grant
    Filed: March 31, 2009
    Date of Patent: December 24, 2013
    Assignee: The Invention Science Fund I, LLC
    Inventors: Edward S. Boyden, Daniel B. Cook, Roderick A. Hyde, Eric C. Leuthardt, Nathan P. Myhrvold, Elizabeth A. Sweeney, Lowell L. Wood, Jr.
  • Publication number: 20130336884
    Abstract: A plurality of artificial red blood cell particles includes each particle of the plurality being substantially monodisperse and each particle having a largest common linear dimension of about 5 ?m to about 10 ?m. The particles can also have a modulus configured such that a particle of the plurality of particles can pass through a tube having an inner diameter of less than about 3 ?m.
    Type: Application
    Filed: May 29, 2013
    Publication date: December 19, 2013
    Applicant: The University of North Carolina at Chapel Hill
    Inventors: Joseph M. DeSimone, Edward T. Samulski
  • Patent number: 8603495
    Abstract: Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue.
    Type: Grant
    Filed: March 31, 2009
    Date of Patent: December 10, 2013
    Assignee: The Invention Science Fund I, LLC
    Inventors: Edward S. Boyden, Daniel B. Cook, Roderick A. Hyde, Eric C. Leuthardt, Nathan P. Myhrvold, Elizabeth A. Sweeney, Lowell L. Wood, Jr.
  • Patent number: 8603494
    Abstract: Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue.
    Type: Grant
    Filed: March 27, 2009
    Date of Patent: December 10, 2013
    Assignee: The Invention Science Fund I, LLC
    Inventors: Edward S. Boyden, Daniel B. Cook, Roderick A. Hyde, Eric C. Leuthardt, Nathan P. Myhrvold, Elizabeth A. Sweeney, Lowell L. Wood, Jr.
  • Patent number: 8603496
    Abstract: Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue.
    Type: Grant
    Filed: March 31, 2009
    Date of Patent: December 10, 2013
    Assignee: The Invention Science Fund I, LLC
    Inventors: Edward S. Boyden, Daniel B. Cook, Roderick A. Hyde, Eric C. Leuthardt, Nathan P. Myhrvold, Elizabeth A. Sweeney, Lowell L. Wood, Jr.
  • Publication number: 20130309167
    Abstract: A contrast marker having a casing and a novel MRI contrast agent comprising metal complexes disposed around, within, or abuting the casing is provided. Such contrast markers may be placed in a strand, with or without a therapy seed, to produce a seeded strand useful for imaging and in connection with brachytherapy.
    Type: Application
    Filed: July 11, 2013
    Publication date: November 21, 2013
    Inventors: Steven J. Frank, Karen Martirosyan